Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ziftomenib + quizartinib
- Development stage
- Unknown
- Lead developer
- Kura Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ziftomenib + quizartinib is an all-oral combination therapy currently being evaluated in a Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML) and myeloid mixed-phenotype acute leukemia (MPAL). Ziftomenib (Komzifti) is a potent, highly selective small molecule inhibitor of the menin-KMT2A (MLL) protein-protein interaction, which is a key epigenetic driver in leukemias harboring NPM1 mutations or KMT2A rearrangements. Quizartinib (Vanflyta) is a selective second-generation type II FLT3 inhibitor that targets proliferative signaling. This combination, primarily investigated in a study led by M.D. Anderson Cancer Center, aims to provide a synergistic therapeutic effect by simultaneously disrupting epigenetic dysregulation and kinase-driven growth in patients with NPM1, KMT2A, or NUP98 mutations.
- Brand names
- KomziftiVanflyta
- Other names
- Ziftomenib and Quizartinib
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)KMT2A
Beyond the preview
Go deeper on ziftomenib + quizartinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ziftomenib + quizartinib.